ALX Oncology Holdings Inc. Common Stock (ALXO) is a publicly traded Healthcare sector company. As of September 28, 2026, ALXO trades at $1.32 with a market cap of $181.14M and a P/E ratio of -0.71. ALXO moved +1.91% today. Year to date, ALXO is +15.93%; over the trailing twelve months it is -26.82%. Its 52-week range spans $0.40 to $2.66. Analyst consensus is strong buy with an average price target of $4.33. Rallies surfaces ALXO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ALX Oncology says Phase 2 ASPEN-06 study shows 40.3% response rate for evorpacept combo: ALX Oncology said its evorpacept combination delivered a 40.3% response rate in the Phase 2 ASPEN-06 study of previously treated HER2-positive gastric cancer. The company will not pursue a U.S. registrational Phase 3 path for the program and kept its mid-2027 target for a topline readout from 80 patients in ASPEN-09-Breast.
| Metric | Value |
|---|---|
| Price | $1.32 |
| Market Cap | $181.14M |
| P/E Ratio | -0.71 |
| EPS | $-1.90 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.66 |
| 52-Week Low | $0.40 |
| Volume | 173.22K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-101.69M |
| Gross Margin | 0.00% |
4 analysts cover ALXO: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.33.